-
France schools protest rumbles on as Macron urges 'respect'
-
Zelensky vows to respond as Moscow silent on 'energy ceasefire'
-
Americans Hall and Woodford win economics Nobel for stabilisation models
-
Thousands march in India's capital to demand election chief resign
-
MEXC Brings AI, TradFi and the Future of Trading to Life at TOKEN2049 Singapore
-
African players in Europe: Mbeumo ends goal drought as United draw
-
Italian rice farmer beats heat with biodiversity haven
-
France's high school students plan fresh protests
-
Stocks mixed as oil prices slip after Trump hails 'energy ceasefire'
-
NZ bank in free speech row over 'explicit' sheep memes
-
Opposition, journalists allege police abuses during India protests
-
China Open champ Zheng withdraws from Wuhan citing fatigue
-
DATA Network joins Sui and Walrus to scale the supply chain for AI training data
-
Brewers edge Dodgers 2-1 in National League Championship Series opener
-
Melbourne man linked to suspected flydubai hijacker condemns 'false accusations'
-
Pope to have surgery to remove lung nodule
-
North Korea fires 'several ballistic missiles' into Sea of Japan
-
Stocks rise as oil prices tumble after Trump hails 'energy ceasefire'
-
El Nino sets temperature record in key Pacific zone: EU monitor
-
Man City charges cloud hangs over Premier League season
-
Nature does not respect borders: UN biodiversity chief
-
Top NATO commander set to issue warning to Russia over any attack
-
World leaders urged to 'course correct' as UN nature goals fall short
-
Software, sprints, trolls: Singapore Grand Prix talking points
-
New York's notorious Rikers jail awaits elusive closure
-
Riyadh airport hit by fresh Houthi strike day after deadly attack
-
Unbeaten 49ers edge Seahawks while Vikings stay perfect
-
Great Western Mining Corporation PLC Announces Exercise of Warrants and Issue of Equity
-
InterContinental Hotels Group PLC Announces Transaction in Own Shares - October 12
-
Yokogawa Brings Publication-Backed Validation from More Than 60,000 Scientific Publications to Its CSU Spinning Disk Confocal Systems with Bioz
-
DataMEDS SI Announces Helomics Receives Medicaid Coverage Policy For Chemofx(R) Assay In Gynecologic Cancers
-
U.S. Energy Secretary Chris Wright, EXIM Chairman John Jovanovic, Nebraska Governor Jim Pillen, Senators Deb Fischer and Pete Ricketts, and Congressman Adrian Smith to Visit NioCorp's Critical Minerals Mine Site
-
Policymakers take on energy shock, rising debt at IMF-World Bank meetings
-
Trump's 'energy ceasefire' sparks confusion as Russia strikes Ukraine
-
Raphael Glucksmann elected centre-left French presidential candidate
-
Dupont double helps Toulouse avoid Bayonne slip-up in Top 14
-
'Dizzy' Lazio join Inter at top of Serie A as Roma, Juve and Milan held
-
Marseille snap losing skid with win at Troyes
-
Jaguars edge Eagles as Packers beat Bears
-
Lula stages mass rally ahead of Brazil's presidential run-off
-
Rays chase first MLB crown as Guardians try to snap drought
-
Poland holds suspect in alleged assassination plot against PM Tusk
-
Hurricane Simon churns off Mexican coast after shift in course
-
Russia hits Ukraine power plants despite Trump energy ceasefire claim
-
'Dizzy' Lazio join Inter at top of Serie A as Roma and AC Milan held
-
Isco's Betis rise back above Real Madrid to third
-
Man City must make 'own noise' amid financial scandal, says Maresca
-
Haaland vows troubled Man City will 'stick together' after beating Liverpool
-
Jaguars down Eagles with wild field goal finish in London
-
Abhishek, Arshdeep guide India to T20 win over West Indies
Appetite-regulating hormones in focus as first Nobel Prizes fall
Research into hormones that regulate appetite is seen leading the race for the Nobel Prize in Medicine, to be awarded Monday -- the first in this year's Nobel season.
At a time when more than one billion people suffer from obesity, research into the hormone called "glucagon-like peptide 1" (GLP-1) could be given the nod for the Nobel Prize in Physiology or Medicine this year, experts said.
A new generation of drugs using GLP-1 agonists -- including blockbuster brands Ozempic, Wegovy and Mounjaro -- has provided a valuable tool to fight obesity and diabetes globally.
"Many are guessing that it (the Nobel Prize in Medicine) will go to the people behind GLP-1," Lars Brostrom, science editor at public broadcaster Sveriges Radio, told AFP.
That could help researchers from major US institutions once again dominate the Nobel Prizes in sciences, which are to be announced this week in Stockholm.
But, even if that happens, US politics is to cast a shadow over them, given budget cuts to science programmes ordered by President Donald Trump's government.
Since January, the US National Institutes of Health (NIH) has terminated 2,100 research grants totalling around $9.5 billion and $2.6 billion in contracts, according to an independent database called Grant Watch.
Such cuts could fuel debate over the growing risk that the United States could lose its edge in scientific research.
"In the post-war period, the US has taken over Germany's role as the world's leading scientific nation," Hans Ellegren, secretary general of the Royal Swedish Academy of Sciences, which awards Nobel Prizes in physics, chemistry, and economics, told AFP.
"When they now start cutting research funding, it threatens the country's position."
- Many contenders -
When it comes to GLP-1, as with many other discoveries, it can be hard to narrow down who exactly deserves to be honoured when many scientists around the world have made significant contributions.
Brostrom said some names often speculated upon are Danish physician Jens Juul Holst, and Joel Habener, a professor of medicine at Harvard, as well as Canadian endocrinologist Daniel Drucker and Yugoslav-born American chemist Svetlana Mojsov.
Despite treatments such as Ozempic being recently introduced, and the Nobel Assembly at the Karolinska Institute more often honouring discoveries that are decades old, "it could also be perfect timing" for GLP-1 recognition "because the discovery itself was made back in the 80s", Brostrom said.
In the same field, research on ghrelin, a hormone that stimulates appetite, could earn a Nobel Prize for two Japanese researchers, Kenji Kangawa and Masayasu Kojima, according to David Pendlebury, who heads research analysis at the firm Clarivate -- which predicts potential Nobel winners based on the number of citations of their work.
Pendlebury said that would also form "a nice bookend to a 1994 discovery" by geneticist Jeffrey Friedman, who discovered another appetite-regulating hormone, leptin, and who has previously been spotlighted by Clarivate.
"We have a combination of very nice discoveries, a hormone for appetite, a hormone that suppresses appetite, and this may also play into a lot of speculation of a prize for the GLP-1," he told AFP.
Clarivate also said the work of German medical professor Andrea Ablasser, American virologist Glen N. Barber, and Chinese-American biochemist Zhijian "James" Chen could be honoured "for elucidating the cGAS-STING pathway, a fundamental mechanism of innate immunity".
It noted that Canadian biologist John E. Dick could also be a contender "for identifying leukaemia stem cells and establishing their relevance in therapy failure".
- 'Invisibility cloak' -
For the Nobel Prize in Physics on Tuesday, experts at Sweden's public radio cited research into metamaterials, which has been buzzed about for several years.
British physicist John B. Pendry has in particular been frequently mentioned for his "invisibility cloak" -- a theoretical method to redirect electromagnetic fields around an object.
The Nobel season continues Wednesday with the prize for chemistry, followed on Thursday by the closely watched literature prize and on Friday the peace prize, which Donald Trump has argued should go to him.
The economics prize wraps up the Nobel season on October 13.
In addition to each honour, the prize includes a diploma, a gold medal, and a check for 11 million Swedish kronor ($1.2 million).
F.Ramirez--AT